<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03845374</url>
  </required_header>
  <id_info>
    <org_study_id>CLI-H004</org_study_id>
    <nct_id>NCT03845374</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized Multi-Center Study of Using the Hyper-CL™ Lens in Subjects Suffering From Bacterial Keratitis</brief_title>
  <official_title>Prospective, Randomized Multi-Center Study of Using the Hyper-CL™ Lens in Subjects Suffering From Bacterial Keratitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eye-yon Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eye-yon Medical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, randomized, open-label, two arms, clinical study aim to evaluate&#xD;
      the efficacy and safety of treatment with Hyper-CL™ lens + Antibiotics compared with&#xD;
      treatment with Antibiotics only, in subjects with Bacterial keratitis.&#xD;
&#xD;
      The design of the Hyper-CL™ lens increases contact time of the antibiotics on the cornea&#xD;
      enabling increased bioavailability of the active drug.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Hyper-CL™ Therapeutic soft contact lenses for short-term wear (up to 7 days) are&#xD;
      indicated for therapeutic use to promote corneal healing and relieve corneal pain by&#xD;
      protecting the cornea during the treatment of acute or chronic pathologies, such as corneal&#xD;
      edema, corneal erosions, entropion, bullous keratopathy, and corneal dystrophies as well as&#xD;
      post-surgical conditions resulting from cataract extraction and corneal surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 13, 2019</start_date>
  <completion_date type="Actual">January 11, 2021</completion_date>
  <primary_completion_date type="Actual">December 22, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>40 patients will be randomized to one of the following 2 groups:&#xD;
Treatment Group 1: Conventional treatment of topical Antibiotics+ Hyper-CL lens&#xD;
Treatment Group 2: Conventional treatment with topical Antibiotics</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Bacterial Keratitis severity score at 14 days</measure>
    <time_frame>From date of randomization up to 14 days</time_frame>
    <description>Will be measured by Bacterial keratitis severity score</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Bacterial Keratitis</condition>
  <arm_group>
    <arm_group_label>Conventional Antibiotics+ Hyper-CL™ lens</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Conventional treatment with topical Antibiotics+ Hyper-CL™ lens</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Antibiotics</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Conventional treatment with topical Antibiotics</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hyper-CL™ lens</intervention_name>
    <description>Use of the Hyper-CL™</description>
    <arm_group_label>Conventional Antibiotics+ Hyper-CL™ lens</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is 18-86 years old&#xD;
&#xD;
          2. Subject with Bacterial keratitis in one eye only&#xD;
&#xD;
          3. Subject with Bacterial Keratitis of at least grade 2 score in Average length of&#xD;
             infiltration and in Average length of epithelial defect (1mm or above)&#xD;
&#xD;
          4. Best-corrected visual acuity of 6/60 or better in the uninvolved eye&#xD;
&#xD;
          5. No prior antibiotic treatment for current Bacterial Keratitis&#xD;
&#xD;
          6. Subject understands the study requirements and the treatment procedures and provides&#xD;
             written Informed Consent before any study-specific tests or procedures are performed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Perforation or imminent perforation of cornea&#xD;
&#xD;
          2. Subject with glaucoma shunts (e.g. Ahmed valve) and or bleb&#xD;
&#xD;
          3. Sign of inflammation in both eyes&#xD;
&#xD;
          4. Severe itching suggesting viral infection or allergy reaction&#xD;
&#xD;
          5. Subepithelial infiltrate suggesting viral infection&#xD;
&#xD;
          6. Dendrite like ulcer or suspecting of Herpes keratitis&#xD;
&#xD;
          7. Previous penetrating keratoplasty&#xD;
&#xD;
          8. No light perception in the affected eye&#xD;
&#xD;
          9. Pregnancy&#xD;
&#xD;
         10. Other active ocular infection&#xD;
&#xD;
         11. Any infiltration suggesting other than bacterial infection e.g. parasite, fungal&#xD;
&#xD;
         12. Any corneal transplant&#xD;
&#xD;
         13. Post refractive surgery&#xD;
&#xD;
         14. Corneal inlays&#xD;
&#xD;
         15. Any other condition which in the opinion of the investigator would place the patient&#xD;
             at undue risk for participation.&#xD;
&#xD;
         16. Participation in another clinical study within the past 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>3109601</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <zip>52621</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>February 7, 2019</study_first_submitted>
  <study_first_submitted_qc>February 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 19, 2019</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

